Marginal Zone Lymphoma
The latest news, research, and perspectives in marginal zone lymphoma (MZL).
Advertisement
Axi-cel showed promising efficacy and safety in patients with relapsed or refractory indolent non-Hodgkin lymphomas.
Two surrogate markers predicted treatment effect on eight-year progression-free survival in patients with extranodal MZL.
Dr. Nastoupil spoke about how the meeting can help clinicians learn how apply knowledge from the latest research.
September is Leukemia and Lymphoma Awareness Month, with Lymphoma Awareness Day marked on September 15.
The composition of T cells in patients with sMZL may affect the efficacy of T-cell-based therapies.
Ibrutinib has a monthly sticker price of $17,000 and was taken by 20,000 people who were beneficiaries of Medicare.
Advertisement
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
The CAR-T targets both CD19 and CD20 antigens for the treatment of relapsed or refractory B-cell malignancies.
Dose reduction may be a strategy to mitigate the risk of cardiac AEs from recurring or worsening in B-cell malignancies.
The European Medicines Agency issued a positive opinion recommending approval of zanubrutinib in adults with MZL.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.